 |
The Leukemia & Lymphoma Society's CMLLinks program: - Provides the most current information about chronic myelogenous leukemia (CML), therapies and clinical trial updates
- Offers many support services to assist patients and family members as they face the challenges of living with CML
- Offers the opportunity to participate in free ongoing education programs where participants can learn from experts about CML and survivorship issues throughout the year, from home or office, at no cost
New* My Clinical Trials Journey
Participate in this personalized and interactive program that follows the stories and experiences of 3 cancer survivors who have participated in clinical trials: Steve, a CML survivor; Roger, a multiple myeloma survivor; and Kim, a lymphoma survivor. Enter Here |
My Personal CML Journey
Participate in this interactive program following the stories and experiences of CML survivors Jack and Paul. Enter Here |
Understanding CML: A Conversation With the Experts
This free telephone education program took place on Wednesday, December 10, 2008 from 8-10pm ET. This program featured Brian J. Druker, MD, Director, Oregon Health & Science, JELD-WEN Chair of Leukemia Research, Investigator, Howard Hughes Medical Institute, Portland OR. and Neil P. Shah, MD, PhD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, Univerisity of California, San Francisco School of Medicine, San Francisco, CA.
View the complete webcast or download the written transcript of this program.
This program was sponsored by The Leukemia & Lymphoma Society and was supported by an unrestricted educational grant from Novartis Oncology
* CE credit is available for this program.
CML News Links: download our free newsletter on treating and living with CML.
We need your help! We are going to redesign our website but that can not be done without your input. Please take a few minutes of your time to complete this survey. Thank you in advance for your help! The eMarketing Team Click here to take the survey. |
|
|
|
|
|
 |
|
|
|
|
|
